KEAP1 and lung cancer: In addition, their group used SUMO1 to treat mutant Keap1 of arginine replacing lysine (K39R) in a subcutaneous tumor model of H1299 lung cancer cell line to study the effect of SUMOylation on activity of Keap1, which showed that the replacement did not affect stability, subcellular localization or dimerization of Keap1.